Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (205)	8/30/2000 12:32:53 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Shares Could Rise to 50 in a Year, Business Week Reports 8/29/00 3:58:00 PM Source: Bloomberg News New Haven, Connecticut, Aug. 29 (Bloomberg) -- Vion Pharmaceuticals Inc. shares could rise to 50 in a year, Business Week reported in its ''Inside Wall Street'' column online, citing Monness, Crespi, Hardt & Co. analyst Richard Yett. Vion is testing an anti-cancer treatment called Tapet that could potentially be as big as Bristol-Myers Squibb Co.'s Taxol, another anti-cancer drug that generates annual revenue of about $1.5 billion, the magazine said, citing Brean Murray Research analyst Brian Ilardo. Tapet uses genetically modified Salmonella bacteria as a way to deliver anti-cancer treatments to a tumor. The modified Salmonella can also shrink and destroy the tumor without damaging normal cells, the magazine said. Vion shares, which have almost tripled over the past year, rose $1.50 to 15 today. The company is based in New Haven, Connecticut. (BW 8/29) For the Web site of Business Week, see {WBWK }. cnetinvestor.com Jim